Discloses an isolated antibody that binds to Low-density lipoprotein receptor-related protein 5 (LRP5), wherein the antibody potentiates Norrin activity and/or Norrin/Fzd4 (Frizzled4) signaling, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence GFTFSSYAMX1, wherein X1 is H or S (SEQ ID NO: 28), (b) HVR-H2 comprising the amino acid sequence GX1ISX2X3GX4STYYADSVKG, wherein X1 is A or G, X2 is A or S, X3 is P or S, X4 is S or W (SEQ ID NO: 26), or SRISSNGGSTYYADSVKG (SEQ ID NO: 27), (c) HVR-H3 comprising the amino acid sequence YYRYAPYRSLGMDV (SEQ ID NO: 23) or WIPQSYPFX1SYKSGFDY, wherein X1 is A or R (SEQ ID NO: 24), (d) HVR-L1 comprising the amino acid sequence RASQGISSYLA (SEQ ID NO: 29) or RASQX1X2X3X4YLA, wherein X1 is A, G, S or V, X2 is I or M, X3 is F, G, S or Y, and X4 is G, S or Y (SEQ ID NO: 30); (e) HVR-L2 comprising the amino acid sequence AASSLQS (SEQ ID NO: 31) or DASX1X2ES, wherein X1 is S or T and X2 is L or R (SEQ ID NO: 32); and (f) HVR-L3 comprising the amino acid sequence QQYYX1YPFT, wherein X1 is L or S (SEQ ID NO: 33). Further discloses related compositions and methods of treating retinopathies.
Anti-lrp5 antibodies and methods of use